新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 辉瑞 » 辉瑞$6.35亿收购百特疫苗业务

辉瑞$6.35亿收购百特疫苗业务

来源:生物谷 2014-07-31 09:38

2014年7月30日讯 /生物谷BIOON/ --百特国际(Baxter International)7月30日宣布,已与辉瑞(Pfizer)签署一项最终协议,将疫苗业务及相关生产设施以6.35亿美元的价格出售给辉瑞。该笔交易预计将于2014年年底完成。

该笔交易将使辉瑞获得百特的脑膜炎疫苗NeisVac-C和脑炎疫苗FSME-IMMUN,以及位于澳大利亚的疫苗生产设施。NeisVac-C用于预防由C群流行性脑脊髓膜炎(MenC)导致的脑膜炎,FSME-IMMUN则用于预防由携带蜱传脑炎(TBE)病毒的蜱虫叮咬所导致的蜱传脑炎。目前,这2种疫苗均已在美国以外国家和地区销售,主要在一些欧洲市场。

目前,辉瑞是美国最大的制药商,该公司周三称,其全球疫苗业务在二季度的销售额为11亿美元。而百特此前公布的二季度数据显示,该公司的疫苗销售仅为1.1亿美元。

百特称,将继续探索战略选择,包括合作或剥离其流感和莱姆病(Lyme disease)研发项目。

百特生物科技公司总裁Ludwig Hantson博士:“该笔交易反映了公司的战略重点,即优化投资组合并加强特定疾病领域。百特的生物科学组织正计划成为一个单独的、独立的全球性生物制药公司。我们将把资源和投资集中于自身强大的研发管线,通过相关技术平台(如基因治疗和生物仿制药),集中于专业核心领域——血液学和免疫学。而辉瑞的疫苗业务被公认具有全球领导地位,我们相信辉瑞将提供持续的必要投资,用于支持和推动这些重要疫苗的供应。”(生物谷Bioon.com)

英文原文:Baxter Announces Divestiture of Commercial Vaccines Business to Pfizer 

DEERFIELD, Ill., July 30, 2014 - Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.

The sale includes the company's commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis (MenC), and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. Both vaccines are currently available outside the United States, primarily in a number of European markets. Baxter continues to explore strategic options, including the potential for partnering or divesting its R&D development programs focused on influenza and Lyme disease.

"This action reflects our strategic priority to optimize the portfolio and enhance focus in specific disease areas as Baxter's BioScience organization prepares to become a separate, independent global biopharmaceutical company.  We are redirecting resources and investing in our robust pipeline centered on core areas of expertise - hematology and immunology - and through technology platforms like gene therapy and biosimilars," said Ludwig Hantson, Ph.D., president of Baxter BioScience. "We are confident that Pfizer, with its recognized global leadership in vaccines, will provide the dedicated, ongoing investments necessary to support and advance the availability of these important vaccines."

Subject to regulatory approvals and other customary closing conditions, the companies expect to close the transaction by the end of 2014. Baxter expects 2014 vaccines revenues to total approximately $300 million and adjusted earnings of approximately $0.25 per diluted share, including approximately $50 million of one-time milestone payments related to the ongoing government collaborations for development of influenza vaccines.  Baxter expects the transaction to be modestly dilutive to fourth quarter 2014 adjusted earnings and dilutive to 2015 adjusted earnings by approximately $0.15 per diluted share.

About Baxter BioScience

Baxter BioScience, one of the largest biotechnology organizations in the world, is a leading provider of therapeutic treatments that save, sustain and improve the lives of people with rare conditions, chronic diseases or limited treatment options. Supported by advanced technical and manufacturing expertise, Baxter BioScience has a broad pipeline built on a legacy of innovation in bleeding disorders and immunology and is expanding to address emerging opportunities in niche areas of oncology as well as technology platforms such as biosimilars.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库